Why Is the Algae Products Market Expanding?
The Algae Products Market is scaling on the back of two converging demand curves rather than one. Per MRFR analysis, the market reached USD 5.92 Billion in 2025 and is projected to reach USD 11.84 Billion by 2035, registering a CAGR of 7.2% (2026–2035). Dietary Supplements — spirulina, chlorella, and microalgae protein powders — hold the largest product share at approximately 38%, while Biofuels is the fastest-growing category at a 9.4% CAGR as sustainable-aviation-fuel offtake agreements mature. Regionally, North America leads with roughly 34% share (USD 2.01 billion in 2025), followed by Europe at approximately 27%; Asia-Pacific is the fastest-growing region at an 8.9% CAGR, anchored by Chinese spirulina export volume and India's National Seaweed Mission.
Regulatory architecture is doing as much work as consumer demand. The U.S. Department of Energy's USD 1.8 billion Bioenergy Technologies Office allocation and the EU's Farm to Fork Strategy have positioned algae-derived ingredients at the center of national decarbonization and nutrition roadmaps, while the U.S. Renewable Fuel Standard and EU RED III both favor advanced, non-food biomass feedstocks that algae biofuel production qualifies under directly. In parallel, major CPG manufacturers eliminating synthetic stabilizers have made seaweed carrageenan reformulation a near-term volume driver rather than a niche one, and the Codex Alimentarius Commission's 2024 work toward international spirulina and algae omega-3 standards signals that cross-border trade friction — currently a structural cost for exporters — is on a multi-year path to easing.
Why These Companies Are Leading?
Instead of focusing on a single business strategy, leadership in this sector is dividing into three separate plays that hardly ever face off. To avoid the light, land, and weather limitations of open-pond producers like Cyanotech, fermentation-based experts like Corbion have explored heterotrophic, dark-fermenter growing, attaining cost structures directly proven in aquaculture feed studies. Instead of treating algal ingredients as a stand-alone growth bet, diversified nutrition and chemical conglomerates like DSM-Firmenich, DIC Corporation, and Cargill view them as a defensible adjunct entrenched inside significantly bigger nutrition, pigment, or hydrocolloid portfolios. A third group is consolidating through acquisitions: in late 2024, Tate & Lyle's acquisition of CP Kelco, De Sangosse's acquisition of AlgaEnergy, and the Cellana–PhytoSmart merger all closed within weeks of one another, indicating that strategic buyers now consider IP derived from algae to be mature enough to buy rather than develop.
Top 10 Global Algae Products Companies — MRFR Rankings (2026)
All revenue figures are validated from official company annual reports, investor relations disclosures, or SEC filings. Where official figures are unavailable for private companies, this is explicitly noted.
|
# |
Company |
HQ |
Revenue (Validated) |
Geo. Presence |
Key Specialization |
Notable Highlight |
|
1 |
Cyanotech Corporation |
Kailua-Kona, HI, USA |
USD 24.2M (FY2025, ended Mar 2025) — SEC Form 10-K |
Hawaii production; distribution in 20+ countries |
Hawaiian Spirulina; BioAstin natural astaxanthin |
FY2025 revenue grew 5% YoY; R&D spend USD 449K (SEC 10-K FY2025) |
|
2 |
DIC Corporation |
Tokyo, Japan |
JPY 1,052.2B group (FY2025) — DIC FY2025 Results Briefing |
60+ countries (global chemicals group) |
Linablue spirulina-derived phycocyanin blue colorant |
Earthrise Nutritionals (CA) cultivates spirulina for solvent-free blue food color |
|
3 |
DSM-Firmenich |
Kaiseraugst, Switzerland |
EUR 9.03B continuing operations (FY2025) — dsm-firmenich FY2025 Results |
Global; Health, Nutrition & Care division |
Algae omega-3 DHA/EPA via Veramaris joint venture |
Veramaris moved from ANH to HNC segment in 2025 portfolio realignment |
|
4 |
Corbion N.V. |
Amsterdam, Netherlands |
EUR 1.27B (FY2025) — Corbion FY2025 Results / Investor Relations |
Netherlands, US, Asia, Americas, EMEA |
AlgaPrime DHA fermentation-derived algae omega-3 |
Millennial Salmon Project confirms AlgaPrime DHA scalability in feed |
|
5 |
Cargill, Inc. |
Minnetonka, MN, USA |
USD 154B total group (FY2025) — Cargill FY2025 Annual Report |
70+ countries |
Seaweed carrageenan hydrocolloids (Texturizing Solutions) |
FY2025 group revenue down 3.75% amid restructuring; algae is a minor adjunct |
|
6 |
CP Kelco (Tate & Lyle plc) |
Atlanta, GA, USA / London, UK (Tate & Lyle) |
GBP 1.73B statutory group revenue (FY2025) — Tate & Lyle FY2025 Results |
38 countries, ~75 locations |
Carrageenan, pectin & seaweed-derived hydrocolloid texturizers |
Acquired by Tate & Lyle for ~USD 1.8B (completed Nov 15, 2024); JM Huber retains ~16% stake |
|
7 |
Roquette Frères |
Lestrem, France |
EUR 4,495M (FY2024) — Roquette Group 2024 Annual Report |
150+ countries, 40+ manufacturing sites |
Microalgae protein (chlorella) within NUTRALYS plant-protein range |
Turnover fell 10% YoY in FY2024 amid IFF Pharma Solutions (~USD 2.85B) acquisition financing |
|
8 |
AlgaEnergy S.A. |
Madrid, Spain |
Undisclosed (private company) |
Europe, Americas, Africa, Asia-Pacific |
Microalgae-based agricultural biostimulants (AgriAlgae, Surety MA) |
Acquired by De Sangosse (Oct 21, 2024); transitioned to PE-backed ag-biologicals ownership |
|
9 |
E.I.D. Parry (India) Limited |
Chennai, India |
INR 38,534 Cr consolidated group (FY2025); Nutraceuticals segment INR 37 Cr — E.I.D. Parry Annual Report FY2024-25 |
41+ spirulina export countries |
Organic Spirulina & Chlorella (Onnaiyur facility) |
Regained EU organic spirulina import license (Oct 2024) after 2-year restriction |
|
10 |
Cellana Inc. |
Kailua-Kona, HI / San Diego, CA, USA |
Undisclosed (private company) |
United States (HI, CA, ME via PhytoSmart) |
ALDUO photobioreactor/open-pond platform; DHA-Omega-3 pet supplements |
Merged with PhytoSmart (Oct 2024); consumer SKU count set to double in 2026 |
*Private company revenues marked 'Undisclosed' where no official published financials are available.
Detailed Company Profiles
1. Cyanotech Corporation | OTCQB: CYAN | Kailua-Kona, HI, USA
Cyanotech is the market's clearest pure-play bet, deriving essentially all revenue from Hawaiian open-pond spirulina and BioAstin astaxanthin rather than treating algae as a side portfolio. FY2025 net sales reached USD 24.2 million, up 5% year-over-year, with gross margin improving nearly three points even as R&D spend was trimmed to USD 449,000 (SEC Form 10-K, FY2025). Its geographic moat — deep, nutrient-rich seawater access unique to its Kona site — is difficult for competitors to replicate outside Hawaii. MRFR views Cyanotech's persistent operating losses despite premium brand positioning as evidence that pure-play open-pond economics remain structurally thin without diversification into fermentation-based production.
2. DIC Corporation | TYO: 4631 | Tokyo, Japan
DIC joins the algae business as a pigment-chemistry conglomerate, using its 50 years of experience in spirulina farming to produce natural food coloring rather than as a nutrition company. According to the DIC FY2025 Results Briefing, the group's net sales in FY2025 were JPY 1,052.2 billion, with the majority of its exposure to algae occurring in its Earthrise A California-based subsidiary of Nutritionals provides water-extracted, solvent-free phycocyanin under the Linablue name for beverage and confectionery coloring. Producers of pure nutraceutical spirulina seldom match DIC's formulation and certification skills, such as COSMOS organic and Halal, due to its chemistry-first origin. MRFR anticipates that DIC's colorant-led entry point will shield it from the pressure on dietary supplement prices that affects its pure-play competitors.
3. DSM-Firmenich | Euronext: DSFIR | Kaiseraugst, Switzerland
DSM-Firmenich's algae exposure runs through the Veramaris joint venture for algae-based DHA/EPA, reported within continuing operations that posted EUR 9.03 billion in net sales for FY2025 (dsm-firmenich FY2025 Results). The strategically significant move was internal: as the group executes its Animal Nutrition & Health divestment to CVC Capital Partners, Veramaris was reclassified from ANH into Health, Nutrition & Care — a deliberate signal that algae-derived omega-3 is being retained as a core consumer-nutrition asset rather than spun off with the rest of animal-feed operations. MRFR reads this reclassification as confirmation that fermentation-derived algae omega-3 is increasingly viewed as human-nutrition infrastructure, not an animal-feed commodity.
4. Corbion N.V. | Euronext: CRBN | Amsterdam, Netherlands
Corbion is the aquaculture-feed benchmark for fermentation-based algae omega-3, reporting EUR 1.27 billion in FY2025 revenue (Corbion FY2025 Results / Investor Relations) from a Health & Nutrition segment anchored by AlgaPrime DHA. Unlike photosynthetic open-pond producers, Corbion's heterotrophic dark-fermenter process removes land, light, and weather constraints, and its cost claims are third-party validated: the Millennial Salmon Project — run with Nofima, Cargill, and MOWI — confirmed AlgaPrime DHA can be added to salmon feed at varying inclusion levels without degrading pellet quality. MRFR sees this multi-partner validation model as a structural advantage competitors without comparable industry consortia access cannot easily replicate.
5. Cargill, Inc. | Private | Minnetonka, MN, USA
Cargill is the market's largest company by absolute revenue — USD 154 billion in FY2025, down 3.75% amid a multi-year restructuring (Cargill FY2025 Annual Report) — yet algae is a minor adjunct rather than a growth pillar, embedded within Cargill Texturizing Solutions' seaweed carrageenan hydrocolloid line and select AlgaPrime DHA feed-trial partnerships. For a trading and protein conglomerate managing volatile grain and cattle margins, algae ingredients function as a hedge against fishmeal and fish-oil price inflation rather than a strategic bet in their own right. MRFR notes that Cargill's scale gives it de facto pricing influence over hydrocolloid sourcing decisions across the food industry, even without a dedicated algae growth strategy.
6. CP Kelco (Tate & Lyle plc) | LSE: TATE | Atlanta, GA, USA / London, UK
CP Kelco's ownership changed decisively in November 2024, when Tate & Lyle completed its approximately USD 1.8 billion acquisition of the carrageenan and pectin specialist from J.M. Huber, which retains roughly 16% of the combined group. Tate & Lyle's FY2025 statutory group revenue reached GBP 1.73 billion, or GBP 2.12 billion on a pro forma basis including a full year of CP Kelco (Tate & Lyle FY2025 Full Year Results). The combination folds seaweed-derived hydrocolloid texturizing technology directly into Tate & Lyle's public sweetening and fortification platforms. MRFR views this as the clearest evidence that algae-hydrocolloid IP has become consolidation bait for larger, publicly listed ingredient platforms.
7. Roquette Frères | Private | Lestrem, France
Roquette reported FY2024 turnover of EUR 4,495 million, down 10% year-over-year (Roquette Group 2024 Annual Report), a decline the company attributes chiefly to commodity pricing normalization rather than its specialty pipeline. Microalgae protein — chlorella — sits inside its broader NUTRALYS plant-protein range, a diversification play rather than a core identity. The more consequential 2024 event was financial: Roquette issued EUR 1.2 billion in inaugural bonds to fund its roughly USD 2.85 billion acquisition of IFF Pharma Solutions, pivoting the group's long-term positioning toward health, nutrition, and pharmaceutical excipients. MRFR expects microalgae protein to remain a minor but strategically consistent thread within this broader pharma-nutrition pivot.
8. AlgaEnergy S.A. | Private | Madrid, Spain
The most significant recent development for AlgaEnergy, a pure-play microalgae agricultural biostimulant specialist (AgriAlgae, Surety MA), was its own acquisition by De Sangosse on October 21, 2024, turning it from an independent, investor-backed B Corp into a subsidiary of a larger crop-input platform backed by private equity. AlgaEnergy does not report revenue because it is a privately held corporation. Despite already operating in nearby agricultural biologicals, De Sangosse opted to purchase rather than develop unique microalgae biostimulant capacity, making the acquisition strategically noteworthy. According to MRFR, this indicates that the microalgae-biostimulant market has matured to the point where specialist cultivation expertise is worth more than internal R&D expenditures.
9. E.I.D. Parry (India) Limited | BSE/NSE: EIDPARRY | Chennai, India
E.I.D. Parry, part of the Murugappa Group, is fundamentally a sugar and ethanol conglomerate — consolidated FY2025 group revenue of INR 38,534 Crore —within which its Nutraceuticals division is financially marginal at just INR 37 Crore (E.I.D. Parry Annual Report FY2024-25). Yet that division operates one of the world's largest single-site organic spirulina and chlorella cultivation facilities at Onnaiyur, exporting to more than 41 countries under USP and international organic certifications. October 2024 brought a pivotal regulatory win: Parry became the first Indian company in nearly two years to regain an EU organic spirulina import license. MRFR views this as disproportionately significant relative to segment revenue, reopening a premium export market Indian spirulina producers had been locked out of.
10. Cellana Inc. | Private | Kailua-Kona, HI / San Diego, CA, USA
The largest enduring structural gap in the algae industry—the gap between commercially established consumer revenue and technically validated production platforms—is addressed by Cellana's October 2024 merger with PhytoSmart. The U.S. Department of Energy's 2016 "State of Technology" reference for algae yields is Cellana's outdoor photosynthetic ALDUO photobioreactor-and-pond system; PhytoSmart contributes an already profitable indoor whole-cell DHA-Omega-3 pet supplement brand that is sold through Amazon and retail, with an anticipated twofold increase in SKUs by 2026. Since Cellana is a private business, revenue is not disclosed. Other early-stage algae-technology developers may use this coupling as a model, according to MRFR: Instead of starting from scratch, combine industrial cultivation intellectual property with an already-existing consumer sales channel.
M&A Activity Tracker
Key verified transactions shaping the Algae Products Market consolidation landscape (2024–2025):
|
Year |
Acquirer |
Target |
Deal Value |
Strategic Objective |
|
2024 |
Tate & Lyle plc |
CP Kelco (from J.M. Huber) |
~USD 1.8 Billion |
Consolidate seaweed-derived carrageenan and pectin hydrocolloid capability into a public sweetening, mouthfeel, and fortification platform. |
|
2024 |
De Sangosse |
AlgaEnergy S.A. |
Undisclosed |
Absorb specialized microalgae biostimulant cultivation IP into a larger agricultural biologicals portfolio rather than build capability internally. |
|
2024 |
Cellana Inc. |
PhytoSmart Inc. |
Undisclosed |
Pair an industrial-scale outdoor photosynthetic algae production platform with an already revenue-generating consumer DHA-Omega-3 pet supplement brand. |
|
2024 |
Roquette Frères |
IFF Pharma Solutions |
~USD 2.85 Billion |
Pivot the group's long-term portfolio toward health, nutrition, and pharmaceutical excipients, funded via inaugural EUR 1.2B bond issuance. |
|
2025 |
Novonesis |
dsm-firmenich Feed Enzymes Alliance stake |
EUR 1.5 Billion |
Enable dsm-firmenich to exit a non-core enzymes joint venture and reallocate capital toward nutrition, health, and beauty priorities, including algae-based DHA/EPA |
Key Trend: M&A in the Algae Products Market clustered sharply in late 2024, with four of five tracked deals closing within a single quarter — Tate & Lyle's CP Kelco acquisition and the Cellana–PhytoSmart merger represent the two most structurally significant moves, consolidating hydrocolloid IP into public platforms while bridging the industry's production-to-revenue gap.
R&D Investment & Innovation Signals
Leading companies are investing in fermentation efficiency, pigment extraction, and consumer-channel commercialization:
- Cyanotech is prioritizing astaxanthin (BioAstin) and spirulina strain optimization to protect margin as it manages constrained Hawaiian pond capacity and reduced FY2025 R&D spend of USD 449,000 (SEC 10-K FY2025).
- DIC Corporation's Earthrise Nutritionals subsidiary is expanding Linablue spirulina-derived phycocyanin production in California and exploring additional pigment and protein extraction from residual spirulina biomass streams for feed applications.
- DSM-Firmenich reclassified its Veramaris algae-DHA/EPA joint venture from Animal Nutrition & Health into Health, Nutrition & Care during its 2025 portfolio restructuring, signaling algae omega-3 is being retained as core human-nutrition infrastructure.
- Corbion continues multi-partner validation of AlgaPrime DHA in aquaculture feed through the Millennial Salmon Project with Nofima, Cargill, and MOWI, confirming stable pellet quality at varying algae-DHA inclusion levels.
- Cargill's Texturizing Solutions unit is deepening seaweed carrageenan hydrocolloid integration across its global food ingredient distribution network, leveraging commodity-trading scale to influence category-wide sourcing economics.
- Roquette is expanding microalgae protein (chlorella) diversification within its NUTRALYS plant-protein platform as it integrates the 2024 IFF Pharma Solutions acquisition into a broader health and nutrition strategy.
- I.D. Parry's Nutraceuticals division regained its EU organic spirulina import license in October 2024, becoming the first Indian company in nearly two years to reopen European export access after a prior regulatory restriction.
- Cellana, following its October 2024 merger with PhytoSmart, is scaling its Sterile Plastic Algal Growth System for indoor whole-cell algae fermentation, with its consumer DHA-Omega-3 pet supplement SKU portfolio expected to double in 2026.